Autism

Michigan

19 Autism Trials near Michigan

Power is an online platform that helps thousands of Autism patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

Learn More About Power
No Placebo
Highly Paid
Stay on Current Meds
Pivotal Trials (Near Approval)
Breakthrough Medication

CM-AT for Autism

Bingham Farms, Michigan
This trial is testing a special enzyme powder called CM-AT to help children with autism digest protein better.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:3 - 17

405 Participants Needed

The overarching goal of the proposed study is to: (a) determine how best to sequence two parent-mediated interventions: a social communication intervention (Project ImPACT, Improving Parents as Communication Teachers) and a disruptive behavior intervention (Parent Training for Disruptive Behavior) and (b) examine moderators and mediators of intervention outcomes.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 48

184 Participants Needed

ML-004 for Autism

Bloomfield Hills, Michigan
This trial is testing the safety of a treatment called ML-004 in adolescents and adults with Autism Spectrum Disorder (ASD). The main goal is to ensure that the treatment does not cause any harmful side effects.
No Placebo Group

Trial Details

Trial Status:Enrolling By Invitation
Trial Phase:Phase 2
Age:12 - 46

120 Participants Needed

ML-004 for Autism Spectrum Disorder

Bloomfield Hills, Michigan
This trial is testing a treatment called ML-004 to see if it can help improve social communication skills in adolescents and adults with Autism Spectrum Disorder (ASD). The study will involve about 150 participants to determine its effectiveness.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:12 - 45

150 Participants Needed

Simplified Language for Autism

East Lansing, Michigan
The long-term study goal is to experimentally evaluate the components (and likely active ingredients) of early language interventions for young children with ASD. The overall objective is to determine how single-word and telegraphic simplification affects real-time language processing and word learning in young children with ASD (relative to full, grammatical utterances). The proposed project will investigate three specific aims: 1) Determine how single-word and telegraphic simplification affects language processing. 2) Determine how single-word and telegraphic simplification affects word learning. 3) Evaluate child characteristics that may moderate the effects of linguistic simplification on language processing and word learning. Aim 1 will test the hypothesis that children with ASD will process full, grammatical utterances faster and more accurately than single-word or telegraphic utterances. Aim 2 will test the hypothesis that full, grammatical utterances will support word learning better than telegraphic or single-word utterances. Aim 3 will test the hypothesis that language and cognitive skills significantly moderate the effects of linguistic simplification on language processing and word learning in young children with ASD.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:1 - 4

104 Participants Needed

Lumateperone for Autism

Bloomfield Hills, Michigan
This is a multicenter, randomized, double-blind, placebo-controlled study in pediatric patients aged 5 to 17 years with a primary diagnosis of irritability associated with Autism Spectrum Disorder (ASD) based on Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition Text Revision (DSM-5-TR) and confirmed by the Kiddie Schedule for Affective Disorders and Schizophrenia Present and Lifetime Version (K-SADS-PL).
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3
Age:5 - 17

174 Participants Needed

This is a multicenter, global, 26-week, open-label study to assess the safety and tolerability of lumateperone in pediatric patients with schizophrenia, bipolar disorder or autism spectrum disorder.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3
Age:5 - 17

500 Participants Needed

This trial is testing the safety and effectiveness of cariprazine in children and teens with schizophrenia, bipolar I disorder, or autism. The goal is to see if the medication is safe and beneficial for use in these young patients.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:5 - 17

310 Participants Needed

Lumateperone for Irritability in Autism

Arlington Heights, Illinois
This is a multicenter, randomized, double-blind, placebo-controlled study in pediatric patients aged 5 to 17 years with a primary diagnosis of irritability associated with Autism Spectrum Disorder (ASD) based on Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition Text Revision (DSM-5-TR) and confirmed by the Kiddie Schedule for Affective Disorders and Schizophrenia Present and Lifetime Version (K-SADS-PL).
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3
Age:5 - 17

174 Participants Needed

Virtual Reality for Autism

Naperville, Illinois
The goal of this randomized clinical trial is to compare and learn about Virtual Reality (VR) in children with autism/Autistic children. The main question it aims to answer is: • Does the Floreo VR clinical product show clinical improvement in autism symptoms? Participants will engage the VR product for twice a week for twelve weeks. They will be randomized to either the Floreo Clinical Product or a VR Control group experience. Researchers will compare the two groups to see if there is an effect on learning specific skills and behaviors.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:5 - 18

100 Participants Needed

The purpose of the study is to see if an internet job interview training program can help people that have autism improve interview skills and access to jobs. Participants will be randomized to use Virtual Interview Training (VIT) or continue services as usual (active control group).
No Placebo Group

Trial Details

Trial Status:Enrolling By Invitation
Trial Phase:Unphased
Age:16 - 26

200 Participants Needed

This study is aiming to see if it is feasible for the intervention Work Chat to be delivered in a completely online setting to adults with autism spectrum disorder.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased

90 Participants Needed

This study is evaluating whether a parent-mediated intervention can improve outcomes for children with autism.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:16 - 33

440 Participants Needed

Nearly 50,000 youth with autism spectrum disorder (ASD) transition from high school to adult life each year with only 25% of these transition-age youth with ASD (TAY-ASD) getting jobs within 2 years of graduation. TAY-ASD's ability to sustain employment is even more challenging due in part to their social cognitive deficits (e.g., poorly reading social cues) that disrupt communicating with customers, coworkers, and supervisors. Research shows nearly 90% of job dismissals among TAY-ASD are attributed to poor work-based social functioning (e.g., poorly communicating with upset customers). The subsequent unemployment has damaging effects on their mental, physical, and economic health. A critical gap in federally-mandated services to support youth with ASD as they transition from school-to-adult life is the lack of evidence-based practice to enhance work-based social functioning. Given that TAY-ASD report computerized training tools (developed by the investigators and others) are highly acceptable and improve their real-world outcomes, the investigators propose to address this critical barrier to sustained employment by developing and evaluating a novel and scalable computerized training tool to enhance participant conversations with customers, coworkers and supervisors at work. The investigators propose to develop and test the effectiveness of Social Cognitive and Affective Learning for Work (Work Chat: An Interactive Virtual Workday), a computerized training tool. Work Chat will have three tiers of instruction designed to help TAY-ASD prepare for effective workplace communication. Tier 1 will adapt existing evidence-based practices to design an e-learning curriculum that trains social cognitive strategies to help guide work-related conversations (e.g., reading social cues or regulating emotions during supervisor feedback). In Tier 2, SIMmersion's PeopleSim® technology will enable TAY-ASD to apply social cognitive strategies learned in Tier 1 to repetitively practice simulated conversations with a fictional customer, coworker, or supervisor. In Tier 3, SIMmersion will innovate PeopleSim to exist in an interactive 3-D environment to create a virtual workday with interconnected activities were the actions made early in the day influence conversations later in the day (e.g., a poor customer interaction may result in constructive feedback from a supervisor). Phase I (Feasibility) was completed with application HUM00177878. Phase II (Efficacy) Aims: Aim 1) Complete Work Chat development using an iterative process that includes initial and ongoing individual-level feedback from Phase I participants and the community and scientific advisory boards to complete the product that will be evaluated in Aims 2-3. Aim 2) Conduct a Randomized Controlled Effectiveness-Implementation hybrid trial in a school setting to evaluate Work Chat. The investigators will recruit and randomly assign n=338 TAY-ASD (90% of sample frame) enrolled in school-based standard transition services (STS) to the Work Chat group (STS+SW) or a STS group (STS). The hypothesis is that STS+SW, compared to STS, will show greater gains in: (H1) social cognition and (H2) work-based social functioning; as well as (H3) reduced anxiety about work-based social encounters, and (H4) greater sustained employment by 9-month follow-up. The investigators will test mechanistic hypotheses (H5a-b) that social cognitive ability (H5a) and work-based social functioning (H5b) mediate the effect of treatment (STS+SW vs. STS) on sustained employment. For the implementation evaluation, the investigators will conduct a multilevel, mixed-method process evaluation of Work Chat's acceptability, appropriateness, and feasibility. Aim 3) Use community participatory research methods to prepare for commercialization. The investigators will conduct a parallel multilevel, mixed method implementation evaluation that focuses on the Work Chat delivery system regarding its feasibility, sustainability, scalability, and generalizability by conduct focus groups with delivery staff and administrators. These groups will discuss potential facilitators and barriers to Work Chat implementation, adoption, and sustainability.
No Placebo Group

Trial Details

Trial Status:Enrolling By Invitation
Trial Phase:Unphased
Age:16+

300 Participants Needed

This research study refines a wellness program designed for caregivers of autistic children called 5Minutes4Myself and further investigates its feasibility. Participants will attend a workshop to consent, participate in focus groups on lifestyle issues, and complete a baseline survey. Participants will have an individualized consultation with a coach to develop their tailored wellness program and be introduced to an app that support habits to build wellness activities into their daily life. The app provides the participant with their goal profile, tailored reminders, weekly check-ins, and delivers a micro-mindfulness program. Coaches will check-in monthly with participants and work together to modify their program as desired. After 4-6 months, participants will gather for a closing workshop to discuss their lifestyle and to evaluate the program. Pre-/post-surveys will examine health, well-being, stress, depression, and mindfulness. The app usability will be assessed using the Modified Systems Usability Scale (MSUS) as well as usage data.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased

25 Participants Needed

Children with poor early language skills are at risk for academic, social, vocational, and health difficulties across the lifespan. Parent training-as part of early language intervention-is a cost-effective option to address this public health issue, but these interventions demonstrate large individual differences in outcomes and barriers to scalability. The purpose of this research is to examine parent-level predictors of early language interaction quality and modifiability during training, which will help increase intervention effectiveness.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:30+

300 Participants Needed

The goal of this collaborative R01 is to demonstrate the therapeutic value and community-wide implementability of an early intervention (EI) platform for toddlers with autism spectrum disorder (ASD) that is completely virtual, from recruitment through intervention. This platform-Early Social Interaction Mobile Coaching (ESI-MC) deploys individual telehealth sessions with coaching and feedback to help families embed intervention in everyday activities. Specifically, the investigators will conduct an effectiveness trial of ESI-MC to address the important question of whether starting evidence-based intervention earlier leads to better outcomes than starting later. The investigators will address this question by using a modified stepped wedge design and blended implementation research to analyze data obtained with ESI-MC start at 18, 24, or 30 months. The investigators will diagnostically ascertain 240 children from a pool of 360 18-month-olds with early signs of autism, 30 in each of 8 US regions (Central and SW Florida; Atlanta, GA; suburbs of Philadelphia, PA; New York City, NY; Cincinnati, OH; Chicago, IL; Seattle, WA; and Los Angeles, CA). Research participants will be recruited using a new virtual platform-My Baby Navigator-linking a new surveillance and screening tool, an app to upload video-recorded home observations and telehealth intervention sessions, and a package of educational resources. The 240 children will be randomly assigned to one of three ESI-MC timing groups. ESI-MC will be delivered by community-based early intervention providers (EIPs) currently working within the the early intervention system in the recruitment regions. The investigators will measure child active engagement and social communication change every 6 months as the primary outcome variables. Outcome measures of developmental level, autism symptoms, and adaptive behavior will be examined to measure differential treatment effects. Maximizing the use of mobile technology, ESI-MC offers the prospect of a community-viable, scalable and sustainable treatment to improve EI services for toddlers with ASD, particularly among minority and low-resource communities.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:15 - 20

240 Participants Needed

This trial is testing pimavanserin, a medication that may help reduce irritability in children and teenagers with autism. The study focuses on kids aged 5 to 17 who have this symptom. Pimavanserin works by balancing brain chemicals to help them feel calmer. The goal is to see if the medication is safe and effective over time.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Age:5 - 18

209 Participants Needed

This trial will investigate if medical cannabis can effectively reduce pain and improve quality of life for patients with chronic conditions. The study will gather data through an online questionnaire about patients' use of cannabis and its effects. Medical cannabis interacts with the body's natural system to help manage pain and other symptoms. Medical cannabis has been increasingly studied and used as an alternative treatment for managing chronic pain, with numerous studies supporting its potential benefits.
Stay on current meds
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:7+

200000 Participants Needed

Why Other Patients Applied

"I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."

ID
Pancreatic Cancer PatientAge: 40

"As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."

IZ
Healthy Volunteer PatientAge: 38

"My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort."

HZ
Arthritis PatientAge: 78

"I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."

AG
Paralysis PatientAge: 50

"I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."

WR
Obesity PatientAge: 58

Know someone looking for new options? Spread the word

Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials

Frequently Asked Questions

How much do Autism clinical trials in Michigan pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

How do Autism clinical trials in Michigan work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Autism trials in Michigan 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Michigan for Autism is 12 months.

How do I participate in a study as a "healthy volunteer"?

Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Michigan several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

Do I need to be insured to participate in a Autism medical study in Michigan?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

What are the newest Autism clinical trials in Michigan?

Most recently, we added Lumateperone for Autism, Lumateperone for Irritability in Autism and Virtual Reality for Autism to the Power online platform.

Is there still a spectrum for autism?

Yes—medical guidelines still call it Autism Spectrum Disorder, but experts no longer picture that spectrum as a single line from “mild” to “severe.” Instead, it’s more like a sound-mixing board with many sliders: social communication, repetitive behaviors, sensory sensitivity, thinking style, and support needs can each sit at different points, creating a unique profile for every autistic person. Clinicians note these differences by assigning support levels (1-3) in each domain so interventions can be tailored rather than ranked.

What is the biggest symptom of autism?

There isn’t one “biggest” symptom of autism; doctors look for a pattern that includes BOTH social-communication differences (like trouble reading body language or carrying on back-and-forth conversation) and restricted, repetitive behaviours or intense interests/sensory sensitivities (such as needing strict routines or reacting strongly to noises). Which of these stands out most varies from person to person, so if you notice a persistent mix of them, the next step is to talk with your GP or a psychologist for a formal autism assessment and tailored support.

Can maternal stress cause autism?

Normal day-to-day worries during pregnancy have not been proven to cause autism. Large studies show that only very severe or long-lasting stress (such as the death of a close relative or a natural disaster) is linked to a small rise in risk—about 2 % to roughly 3 %—and even that link may partly reflect other genetic or environmental factors. Taking steps to manage high stress is good for overall maternal and baby health, but parents should not blame themselves or everyday stressors if a child is later diagnosed with autism.

What is the life expectancy of someone with autism?

Large registry studies (e.g., Sweden 2016, Denmark 2022) find that autistic people, on average, die 15–20 years earlier than non-autistic peers, with a median age of death around the mid-50s; the figure is lower (≈ 40s) when someone also has intellectual disability or uncontrolled epilepsy and higher (late 50s or beyond) when those conditions are absent. The gap is driven less by autism itself than by treatable or preventable issues—seizures, heart disease, accidents and suicide—so good medical follow-up, mental-health support and safety planning can help many autistic individuals live into typical older age.

What is the best treatment for autism in the world?

There is no one “best” treatment for every person with autism; the strongest evidence shows that progress comes from an individualized program that blends proven developmental-behavioral therapies (such as Applied Behavior Analysis or other naturalistic approaches) with speech-language and occupational therapy, parent coaching, and tailored educational supports. A multidisciplinary team adjusts this mix over time—and may add medication for anxiety, ADHD, or sleep problems—so the plan fits the person’s specific strengths, challenges, and goals, which is what international guidelines recommend for the best results.

Is autism overdiagnosed?

Rates of autism have risen sharply (e.g., from about 1 in 150 U.S. children in 2000 to 1 in 36 today), but most of that jump comes from broader definitions, better screening, and shifting other labels to “autism,” not from a sudden epidemic. Studies suggest roughly 1 in 10 people once given the label later lose it—evidence of some over-diagnosis—yet girls, adults, and many minority children are still frequently missed, so the real problem is uneven diagnosis rather than simply “too much” or “too little.” A careful, multidisciplinary assessment that also checks for ADHD, language disorders, anxiety, and other look-alike conditions is the best way to get an accurate answer for any individual.

Who carries the autism gene?

There is no single “autism gene.” Autism risk comes from a mix of many common genetic variants, rare mutations, and sometimes new (de-novo) changes that neither parent had; these can be inherited from either mother or father, while factors like higher paternal age and the female-protective effect can influence how that risk shows up. In short, either parent—or neither, if the change is new—can pass along genetic risk, so talking with a genetic counselor is the best way to understand a specific family’s situation.

Which state has the highest rate of autism?

In the latest CDC ADDM study, the surveillance area in California recorded the highest autism rate: roughly 4.5 % of 8-year-olds (about 45 children per 1,000). However, ADDM covers only parts of 11 states and other tracking systems use different methods, so rankings can change if you look at school records, insurance data, or adult estimates—meaning the numbers are useful for spotting trends, not declaring a single “most-autistic” state.

Has anyone ever overcome autism?

Autism is a lifelong neuro-developmental difference, so people don’t “overcome” it in the sense of being cured; instead, most continue to be autistic throughout life. With early, individualized supports and ongoing accommodations, many children and adults make major gains—some even lose the formal diagnosis—yet they often keep certain autistic traits and still benefit from understanding and acceptance. The practical aim is therefore not to erase autism but to build skills, reduce distress, and create environments where each autistic person can thrive.

What was autism called in the 1980s?

In the early-1980s diagnostic manual (DSM-III, 1980) autism was officially listed as “Infantile Autism,” and in the 1987 revision (DSM-III-R) the name was changed to “Autistic Disorder” under the larger category of “Pervasive Developmental Disorders.” Outside the U.S., doctors using the World Health Organization’s ICD-9 still called it “Childhood Autism.” In everyday practice, people might also have heard “Kanner’s autism” or “childhood psychosis,” but the two formal labels you would have seen on a medical chart during that decade were “Infantile Autism” at the start of the 1980s and “Autistic Disorder” by the end.

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security